These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 38325898)

  • 21. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.
    Furie R; Petri M; Zamani O; Cervera R; Wallace DJ; Tegzová D; Sanchez-Guerrero J; Schwarting A; Merrill JT; Chatham WW; Stohl W; Ginzler EM; Hough DR; Zhong ZJ; Freimuth W; van Vollenhoven RF;
    Arthritis Rheum; 2011 Dec; 63(12):3918-30. PubMed ID: 22127708
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus.
    Furie R; Khamashta M; Merrill JT; Werth VP; Kalunian K; Brohawn P; Illei GG; Drappa J; Wang L; Yoo S;
    Arthritis Rheumatol; 2017 Feb; 69(2):376-386. PubMed ID: 28130918
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial:
    Morand EF; Trasieva T; Berglind A; Illei GG; Tummala R
    Ann Rheum Dis; 2018 May; 77(5):706-713. PubMed ID: 29420200
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Disease trajectory of SLE clinical endpoints and covariates affecting disease severity and probability of response: Analysis of pooled patient-level placebo (Standard-of-Care) data to enable model-informed drug development.
    Goteti K; French J; Garcia R; Li Y; Casset-Semanaz F; Aydemir A; Townsend R; Mateo CV; Studham M; Guenther O; Kao A; Gastonguay M; Girard P; Benincosa L; Venkatakrishnan K
    CPT Pharmacometrics Syst Pharmacol; 2023 Feb; 12(2):180-195. PubMed ID: 36350330
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study.
    Furie RA; Leon G; Thomas M; Petri MA; Chu AD; Hislop C; Martin RS; Scheinberg MA;
    Ann Rheum Dis; 2015 Sep; 74(9):1667-75. PubMed ID: 24748629
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Which outcome measures in SLE clinical trials best reflect medical judgment?
    Thanou A; Chakravarty E; James JA; Merrill JT
    Lupus Sci Med; 2014; 1(1):e000005. PubMed ID: 25396057
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical trial parameters that influence outcomes in lupus trials that use the systemic lupus erythematosus responder index.
    Kalunian KC; Urowitz MB; Isenberg D; Merrill JT; Petri M; Furie RA; Morgan-Cox MA; Taha R; Watts S; Silk M; Linnik MD
    Rheumatology (Oxford); 2018 Jan; 57(1):125-133. PubMed ID: 29045736
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anifrolumab for systemic lupus erythematosus with multi-refractory skin disease: A case series of 18 patients.
    Flouda S; Emmanouilidou E; Karamanakos A; Koumaki D; Katsifis-Nezis D; Repa A; Bertsias G; Boumpas D; Fanouriakis A
    Lupus; 2024 Oct; 33(11):1248-1253. PubMed ID: 39098049
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessments of fatigue and disease activity in patients with systemic lupus erythematosus enrolled in the Phase 2 clinical trial with blisibimod.
    Petri MA; Martin RS; Scheinberg MA; Furie RA
    Lupus; 2017 Jan; 26(1):27-37. PubMed ID: 27353505
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mezagitamab in systemic lupus erythematosus: clinical and mechanistic findings of CD38 inhibition in an autoimmune disease.
    McDonnell SRP; Nguyen VA; Walton NM; Merkwirth C; Hong F; Berg D; Muensterman ET; Furie RA
    Lupus Sci Med; 2024 Mar; 11(1):. PubMed ID: 38453421
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical meaningfulness of a British Isles Lupus Assessment Group-based Composite Lupus Assessment response in terms of patient-reported outcomes in moderate to severe systemic lupus erythematosus: a post-hoc analysis of the phase 3 TULIP-1 and TULIP-2 trials of anifrolumab.
    Strand V; O'Quinn S; Furie RA; Morand EF; Kalunian KC; Schwetje EG; Abreu G; Tummala R
    Lancet Rheumatol; 2022 Mar; 4(3):e198-e207. PubMed ID: 38288936
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and Safety of Ustekinumab in Patients With Active Systemic Lupus Erythematosus: Results of a Phase II Open-label Extension Study.
    van Vollenhoven RF; Hahn BH; Tsokos GC; Lipsky P; Gordon RM; Fei K; Lo KH; Chevrier M; Rose S; Berry P; Yao Z; Karyekar CS; Zuraw Q
    J Rheumatol; 2022 Apr; 49(4):380-387. PubMed ID: 34853089
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial.
    Wallace DJ; Strand V; Merrill JT; Popa S; Spindler AJ; Eimon A; Petri M; Smolen JS; Wajdula J; Christensen J; Li C; Diehl A; Vincent MS; Beebe J; Healey P; Sridharan S
    Ann Rheum Dis; 2017 Mar; 76(3):534-542. PubMed ID: 27672124
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study.
    Khamashta M; Merrill JT; Werth VP; Furie R; Kalunian K; Illei GG; Drappa J; Wang L; Greth W;
    Ann Rheum Dis; 2016 Nov; 75(11):1909-1916. PubMed ID: 27009916
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Organ system improvements in Japanese patients with systemic lupus erythematosus treated with belimumab: A subgroup analysis from a phase 3 randomized placebo-controlled trial.
    Tanaka Y; Bass D; Chu M; Egginton S; Ji B; Roth D
    Mod Rheumatol; 2020 Mar; 30(2):313-320. PubMed ID: 31199180
    [No Abstract]   [Full Text] [Related]  

  • 36. Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial.
    Merrill JT; Shanahan WR; Scheinberg M; Kalunian KC; Wofsy D; Martin RS
    Ann Rheum Dis; 2018 Jun; 77(6):883-889. PubMed ID: 29563108
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Performance of SLE responder index and lupus low disease activity state in real life: A prospective cohort study.
    Ramirez GA; Canti V; Moiola L; Magnoni M; Rovere-Querini P; Coletto LA; Dagna L; Manfredi AA; Bozzolo EP
    Int J Rheum Dis; 2019 Sep; 22(9):1752-1761. PubMed ID: 31379114
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Systemic Lupus Erythematosus (SLE) Responder Index response is associated with global benefit for patients with SLE.
    Furie R; Wang L; Illei G; Drappa J
    Lupus; 2018 May; 27(6):955-962. PubMed ID: 29460699
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.
    Merrill JT; van Vollenhoven RF; Buyon JP; Furie RA; Stohl W; Morgan-Cox M; Dickson C; Anderson PW; Lee C; Berclaz PY; Dörner T
    Ann Rheum Dis; 2016 Feb; 75(2):332-40. PubMed ID: 26293163
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low-dose belimumab for patients with systemic lupus erythematosus at low disease activity: protocol for a multicentre, randomised, double-blind, placebo-controlled clinical trial.
    Sun F; Huang W; Chen J; Zhao L; Zhang D; Wang X; Wan W; Dai SM; Chen S; Li T; Ye S
    Lupus Sci Med; 2022 Feb; 9(1):. PubMed ID: 35105722
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.